140 related articles for article (PubMed ID: 29233603)
1. Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma.
Sönnichsen R; Hennig L; Blaschke V; Winter K; Körfer J; Hähnel S; Monecke A; Wittekind C; Jansen-Winkeln B; Thieme R; Gockel I; Grosser K; Weimann A; Kubick C; Wiechmann V; Aigner A; Bechmann I; Lordick F; Kallendrusch S
Clin Colorectal Cancer; 2018 Jun; 17(2):e189-e199. PubMed ID: 29233603
[TBL] [Abstract][Full Text] [Related]
2. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy.
Theile D; Grebhardt S; Haefeli WE; Weiss J
Biochem Pharmacol; 2009 Dec; 78(11):1366-73. PubMed ID: 19622348
[TBL] [Abstract][Full Text] [Related]
3. 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype.
Chang TC; Yeh CT; Adebayo BO; Lin YC; Deng L; Rao YK; Huang CC; Lee WH; Wu AT; Hsiao M; Wu CH; Wang LS; Tzeng YM
Toxicol Appl Pharmacol; 2015 Oct; 288(2):258-68. PubMed ID: 26235807
[TBL] [Abstract][Full Text] [Related]
4. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.
Fior R; Póvoa V; Mendes RV; Carvalho T; Gomes A; Figueiredo N; Ferreira MG
Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8234-E8243. PubMed ID: 28835536
[TBL] [Abstract][Full Text] [Related]
5. Organotypic slice cultures of human gastric and esophagogastric junction cancer.
Koerfer J; Kallendrusch S; Merz F; Wittekind C; Kubick C; Kassahun WT; Schumacher G; Moebius C; Gaßler N; Schopow N; Geister D; Wiechmann V; Weimann A; Eckmann C; Aigner A; Bechmann I; Lordick F
Cancer Med; 2016 Jul; 5(7):1444-53. PubMed ID: 27073068
[TBL] [Abstract][Full Text] [Related]
6. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
Kap EJ; Seibold P; Scherer D; Habermann N; Balavarca Y; Jansen L; Zucknick M; Becker N; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
Int J Cancer; 2016 Jun; 138(12):2993-3001. PubMed ID: 26835885
[TBL] [Abstract][Full Text] [Related]
7. In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
Cho YB; Lee WY; Song SY; Choi SH; Shin HJ; Ahn KD; Lee JM; Kim HC; Yun SH; Chun HK
Eur J Surg Oncol; 2009 Sep; 35(9):951-6. PubMed ID: 19181477
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer.
Martin SZ; Wagner DC; Hörner N; Horst D; Lang H; Tagscherer KE; Roth W
BMC Cancer; 2019 Nov; 19(1):1030. PubMed ID: 31675944
[TBL] [Abstract][Full Text] [Related]
9. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
[TBL] [Abstract][Full Text] [Related]
11. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells.
Berindan-Neagoe I; Braicu C; Pileczki V; Cojocneanu Petric R; Miron N; Balacescu O; Iancu D; Ciuleanu T
J Gastrointestin Liver Dis; 2013 Mar; 22(1):37-43. PubMed ID: 23539389
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
Whitehouse PA; Knight LA; Di Nicolantonio F; Mercer SJ; Sharma S; Cree IA;
Anticancer Drugs; 2003 Jun; 14(5):369-75. PubMed ID: 12782944
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of chemotherapy on oncogenic pathways in colorectal cancer.
Spartalis C; Schmidt EM; Elmasry M; Schulz GB; Kirchner T; Horst D
Cancer Sci; 2019 Aug; 110(8):2529-2539. PubMed ID: 31119819
[TBL] [Abstract][Full Text] [Related]
16. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.
Lim CY; Chang JH; Lee WS; Lee KM; Yoon YC; Kim J; Park IY
Pancreatology; 2018 Dec; 18(8):913-927. PubMed ID: 30292644
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Kuo T; Cho CD; Halsey J; Wakelee HA; Advani RH; Ford JM; Fisher GA; Sikic BI
J Clin Oncol; 2005 Aug; 23(24):5613-9. PubMed ID: 16110021
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
19. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
20. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
